ARGX
Price
$393.42
Change
+$10.08 (+2.63%)
Updated
May 2, 6:59 PM EST
6 days until earnings call
NRBO
Price
$3.73
Change
+$0.06 (+1.64%)
Updated
May 3, 10:05 AM EST
Ad is loading...

ARGX vs NRBO ᐉ Comparison: Which is Better to Invest?

Header iconARGX vs NRBO Comparison
Open Charts ARGX vs NRBOBanner chart's image
argenx SE
Price$393.42
Change+$10.08 (+2.63%)
Volume$79.75K
CapitalizationN/A
NeuroBo Pharmaceuticals
Price$3.73
Change+$0.06 (+1.64%)
Volume$350
CapitalizationN/A
View a ticker or compare two or three
ARGX vs NRBO Comparison Chart

Loading...

ARGXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
NRBODaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
ARGX vs. NRBO commentary
May 03, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARGX is a Hold and NRBO is a StrongBuy.

COMPARISON
Comparison
May 03, 2024
Stock price -- (ARGX: $393.42 vs. NRBO: $3.73)
Brand notoriety: ARGX and NRBO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARGX: 80% vs. NRBO: 12%
Market capitalization -- ARGX: $23.13B vs. NRBO: $18.3M
ARGX [@Biotechnology] is valued at $23.13B. NRBO’s [@Biotechnology] market capitalization is $18.3M. The market cap for tickers in the [@Biotechnology] industry ranges from $559.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.61B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARGX’s FA Score shows that 1 FA rating(s) are green whileNRBO’s FA Score has 1 green FA rating(s).

  • ARGX’s FA Score: 1 green, 4 red.
  • NRBO’s FA Score: 1 green, 4 red.
According to our system of comparison, ARGX is a better buy in the long-term than NRBO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARGX’s TA Score shows that 5 TA indicator(s) are bullish while NRBO’s TA Score has 5 bullish TA indicator(s).

  • ARGX’s TA Score: 5 bullish, 5 bearish.
  • NRBO’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, NRBO is a better buy in the short-term than ARGX.

Price Growth

ARGX (@Biotechnology) experienced а +6.73% price change this week, while NRBO (@Biotechnology) price change was +21.90% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.32%. For the same industry, the average monthly price growth was -0.52%, and the average quarterly price growth was +1244.27%.

Reported Earning Dates

ARGX is expected to report earnings on Jul 25, 2024.

NRBO is expected to report earnings on Mar 29, 2024.

Industries' Descriptions

@Biotechnology (+5.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ARGX with price predictions.
OPEN
A.I.dvisor published
a Summary for NRBO with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
ARGX($23.1B) has a higher market cap than NRBO($18.3M). ARGX YTD gains are higher at: 3.415 vs. NRBO (0.904).
ARGXNRBOARGX / NRBO
Capitalization23.1B18.3M126,230%
EBITDAN/AN/A-
Gain YTD3.4150.904378%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
ARGX vs NRBO: Fundamental Ratings
ARGX
NRBO
OUTLOOK RATING
1..100
133
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
20
Undervalued
PROFIT vs RISK RATING
1..100
22100
SMR RATING
1..100
9398
PRICE GROWTH RATING
1..100
5963
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NRBO's Valuation (20) in the null industry is somewhat better than the same rating for ARGX (55) in the Pharmaceuticals Other industry. This means that NRBO’s stock grew somewhat faster than ARGX’s over the last 12 months.

ARGX's Profit vs Risk Rating (22) in the Pharmaceuticals Other industry is significantly better than the same rating for NRBO (100) in the null industry. This means that ARGX’s stock grew significantly faster than NRBO’s over the last 12 months.

ARGX's SMR Rating (93) in the Pharmaceuticals Other industry is in the same range as NRBO (98) in the null industry. This means that ARGX’s stock grew similarly to NRBO’s over the last 12 months.

ARGX's Price Growth Rating (59) in the Pharmaceuticals Other industry is in the same range as NRBO (63) in the null industry. This means that ARGX’s stock grew similarly to NRBO’s over the last 12 months.

ARGX's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as NRBO (100) in the null industry. This means that ARGX’s stock grew similarly to NRBO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARGXNRBO
RSI
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
67%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
65%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
75%
Declines
ODDS (%)
Bearish Trend 9 days ago
67%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
68%
Bullish Trend 1 day ago
74%
Aroon
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
ARGXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
NRBODaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PUMP9.160.23
+2.58%
ProPetro Holding Corp
CTRA27.160.25
+0.93%
Coterra Energy
PKBK16.710.10
+0.60%
Parke Bancorp
INDP2.01-0.02
-1.05%
Indaptus Therapeutics
SPT48.15-1.76
-3.53%
Sprout Social

ARGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARGX has been loosely correlated with BBIO. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ARGX jumps, then BBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARGX
1D Price
Change %
ARGX100%
+2.63%
BBIO - ARGX
52%
Loosely correlated
+2.63%
NRBO - ARGX
45%
Loosely correlated
+1.36%
MDGL - ARGX
43%
Loosely correlated
+2.59%
BLUE - ARGX
42%
Loosely correlated
-0.66%
AXON - ARGX
40%
Loosely correlated
+1.66%
More

NRBO and

Correlation & Price change

A.I.dvisor indicates that over the last year, NRBO has been loosely correlated with TCRT. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if NRBO jumps, then TCRT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NRBO
1D Price
Change %
NRBO100%
+1.36%
TCRT - NRBO
50%
Loosely correlated
+5.43%
ARGX - NRBO
45%
Loosely correlated
+2.63%
BLUE - NRBO
37%
Loosely correlated
-0.66%
SYRE - NRBO
37%
Loosely correlated
+7.09%
CMRA - NRBO
34%
Loosely correlated
-16.90%
More